neoplasm of mature T-cells or NK-cells
diseaseOn this page
Also known as mature T and NK neoplasmsmature T-cell and NK-cell neoplasmmature T-cell neoplasm
Summary
neoplasm of mature T-cells or NK-cells (MONDO:0005169) is a cancer and 2 clinical trials. Top therapeutic interventions include copanlisib, gemcitabine, and nelfinavir mesylate. A subtype of T-cell and NK-cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | neoplasm of mature T-cells or NK-cells |
| Mondo ID | MONDO:0005169 |
| EFO | EFO:0002426 |
| NCIT | C27909 |
| UMLS | C1334640 |
| MedGen | 233675 |
| GARD | 0024159 |
| Is cancer (heuristic) | yes |
Also known as: mature T and NK neoplasms · mature T-cell and NK-cell neoplasm · mature T-cell neoplasm
Disease family
An umbrella term covering 4 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells
Related subtypes (1): T lymphoblastic leukemia/lymphoma
Subtypes (4): mature T-cell and NK-cell non-Hodgkin lymphoma, chronic lymphoproliferative disorder of NK-cells, peripheral T-cell lymphoma, not otherwise specified, EBV-positive T-cell lymphoproliferative disorder of childhood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03052933 | PHASE1/PHASE2 | COMPLETED | Copanlisib and Gemcitabine in Relapsed/Refractory PTCL |
| NCT01164709 | PHASE1 | COMPLETED | Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| COPANLISIB | 4 | 1 |
| GEMCITABINE | 4 | 1 |
| NELFINAVIR MESYLATE | 4 | 1 |
| CHEMBL365442 | 0 | 1 |
Related Atlas pages
- Drugs: Copanlisib, Gemcitabine, Nelfinavir